Synthace, a Digital Experiment Platform for Life Science R&D, Records Strongest Year Yet

LONDON & BOSTON–(BUSINESS WIRE)–#Automation–Today, Synthace, a digital life science experiment platform, announces it has had its most successful year on record with major adoption and expansion with customers, industry recognition, product innovation, and a key hire at board level. Major adoption and expansion among the top 100 pharma Synthace experienced 94% annual recurring revenue growth, … [Read more…]

Adeno Associated Virus Vector Manufacturing Global Market Report 2023: Robust Pipelines for Gene Therapies and Vaccines Bolsters Sector – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By Therapeutic Area, By Region, And Segment Forecasts, 2023 – 2030” report has been added to ResearchAndMarkets.com’s offering. The global adeno associated virus vector manufacturing market size is expected to reach … [Read more…]

Global Neurovascular Thrombus Management Global Market Report 2023: Sector to Reach $1.9 Billion by 2029 at a 5.9% CAGR – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Neurovascular Thrombus Management Market Size, Share & Trends Analysis 2023-2029 MedCore Includes: Stent Retrievers and Aspiration Catheters” report has been added to ResearchAndMarkets.com’s offering. The global market for neurovascular thrombus management was valued at $1.3 billion in 2022 and is anticipated to grow at a CAGR of 5.9% during the forecast period, … [Read more…]

Lionrock Recovery Launches Free Program for Companies Addressing Substance Use Disorder in the Workplace

The Online Program Challenges Companies to Break the Stigma of Addiction in the Workplace, Bringing Expert Training and Support to HR Leaders, Managers, and Employees REDWOOD CITY, Calif.–(BUSINESS WIRE)–#Addiction–On a mission to eliminate the stigma and impact of substance use disorders (SUDs) in the workplace, Lionrock–the inventor of telehealth for SUD treatment and recovery services … [Read more…]

U.S Mammography and Breast Imaging Market Outlook Report 2022: Mammography Department Budgets Anticipated to Grow at an Estimated 9.7% Each Year from 2023 Through 2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “2022 U.S Mammography and Breast Imaging Market Outlook Report” report has been added to ResearchAndMarkets.com’s offering. Mammography departments are anticipating that their current budgets will grow by an estimated 9.7% per year from 2023 through 2025, according to the 2022 Mammography and Breast Imaging Market Outlook Report. For the first time in over … [Read more…]

Global Bioreactors and Fermenters Market Report 2023: Distribution by Type of Product, Fabrication Material, Type of Bioprocess, Type of Biologics, and Key Geographical Regions – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Bioreactors and Fermenters Market: Distribution by Type of Product, Fabrication Material, Type of Bioprocess, Type of Biologics, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current market landscape and the likely future potential of the … [Read more…]

Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study

LONDON & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial (ALS-6000-101) of AVA6000. This follows the approval of an amended clinical trial protocol by the Medical … [Read more…]

BenevolentAI Announces Top-Line Phase IIa Results for Its Topical pan-Trk Inhibitor BEN-2293 (1%) in Mild-to-Moderate Atopic Dermatitis

Successfully met primary endpoint with BEN-2293 found to be safe and well tolerated Secondary efficacy endpoints, to reduce itch and inflammation, were not achieved. However, initial analyses in the Per-Protocol population have shown a statistically significant treatment effect in Eczema Area and Severity Index (EASI) change from baseline for patients with an Atopic Dermatitis affected … [Read more…]

Revitalist Announces Unit Private Placement

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia–(BUSINESS WIRE)–#education–Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) (the ”Company” or “Revitalist”), is pleased to announce a non-brokered private placement consisting of the issuance of up 85,000,000 units (each, a “Unit”) … [Read more…]

CORRECTING and REPLACING Jarman’s Midwest Cleaning Systems, Inc. Issues Voluntary Nationwide Recall of Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution, SOFT HANDS Alcohol Antiseptic 80% Topical Solution Hand Sanitizer…

CANTON, S.D.–(BUSINESS WIRE)–Please replace the release dated March 28, 2023, with the following corrected version due to multiple revisions. The updated release reads: Jarman’s Midwest Cleaning Systems, Inc. Issues Voluntary Nationwide Recall of Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution, SOFT HANDS Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution, and Isopropyl … [Read more…]